Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
P11117
UPID:
PPAL_HUMAN
Alternative names:
-
Alternative UPACC:
P11117; E9PCI1; Q561W5; Q9BTU7
Background:
Lysosomal acid phosphatase, encoded by the gene with the accession number P11117, plays a crucial role in the lysosomal degradation pathway. This enzyme is pivotal for the dephosphorylation processes, facilitating the breakdown of phosphomonoesters into inorganic phosphate and alcohol, a fundamental step in the cellular recycling mechanism.
Therapeutic significance:
Understanding the role of Lysosomal acid phosphatase could open doors to potential therapeutic strategies. Its critical function in cellular metabolism and recycling underscores its potential as a target for therapeutic intervention in diseases where these processes are disrupted.